LARSEN-&-TOUBRO-INFOTECH
6.2.2020 12:02:04 CET | Business Wire | Pressemeddelelse
Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), er en global virksomhed inden for teknologirådgivning og digitale løsninger, har udvidet sin aftale med OKQ8 AB Scandinavia. I løbet af de næste fem år vil denne aftale tranformere applikationer og OKQ8’s infrastruktur landskab med tjenester der omfatter Infrastruktur-as-a-Service (IaaS), Sikkerhedstjenester, Applikationsdrift, Vedligeholdelse og Udvikling, hvilket vil resultere i forbedret stabilitet, tilgængelighed og forudsigelighed af it-driften.
OKQ8, der har hovedkvarter i Stockholm, er en af Skandinaviens største brændstofvirksomheder med en omsætning på over 39 mia. SEK og tæt på 1000 stationer over hele Danmark og Sverige. LTI har været partner med OKQ8 siden 2017, og denne udvidede aftaler er et resultat af, hvad dette partnerskab har skabt gennem årene. Som en strategisk partner vil LTI udnytte sine omfattende evner indenfor analyse, automatisering og KI til at levere disse servicer til OKQ8.
Mikael Pålsson, CIO, OKQ8 , udtaler, “For at kunne betjene vores kunder bedre er det afgørende for OKQ8 at integrere vores økosystem som består af brændstofstationer, dagligvarebutikker, bilvaske, biludlejninger samt økonomi- og forsikringsservicer. Som vores strategiske partner bringer LTI den rette erfaring, teknologiske kompetence og kulturelle tilpasning der sikrer, at dette program bliver en fuldkommen succes.”
Arun Sankaranarayanan, Chief Business Officer, LTI Nordics , udtaler, “Siden begyndelsen I 1999 har OKQ8 konsekvent sat høje standarder for teknologiudnyttelse og ekspertise indenfor kundeservice. Vi er glade for at udvide vores partnerskab med OKQ8 for at designe næste generations arkitektur og opfylde virksomhedens vision for digital transformation. LTI vil udnytte sine evner indenfor eksponentielle teknologier og kundecentrisk tilgang til at hjælpe OKQ8 med at nå sine strategiske mål.”
LTI har en stærk tilstedeværelse I hele Norden og samarbejder med førende virksomheder for at hjælpe dem med at konkurrere effektivt i en verden i forandring.
Om LTI:
LTI (NSE: LTI) er en global virksomhed inden for teknologirådgivning og digitale løsninger, der hjælper over 420 klienter med at få succes i en konvergerende verden. Med operationer I 32 lande går vi den ekstra mil for vores klienter og fremskynder deres digitale transformation med LTIs Mosaic platform, som muliggør deres mobile, sociale, analytiske, IoT og cloud-baserede rejser. Vi blev grundlagt I 1997 som et datterselskab af Larsen & Toubro Limited, og vores unikke arv giver os en uovertruffen ekspertise til at løse de mest komplekse udfordringer for virksomheder på tværs af alle brancher. Hver dag giver vores team, på over 30.000 LTI-medarbejdere, vores kunder mulighed for at forbedre effektiviteten af deres forretnings- og teknologidrift samt levere værdi til deres kunder, medarbejdere og aktionærer. Læs mere på http://www.Lntinfotech.com eller følg os på @LTI_Global
Om OKQ8 AB :
OKQ8 Scandinavia: Den foretrukne mulighed for bæredygtig bevægelse
OKQ8 Scandinavia har operationer I Sverige og Danmark og er en af Skandinaviens største brændstofvirksomheder. Vi er en organisation med omkring 5000 ansatte som er engagerede, kundeorienterede og har fokus på bæredygtighed. Vi arbejder aktivt på at drive udviklingen af mere klima- og miljøvenlige brændstoffer og produkter fremad, på at reducere ulighed og på at bidrage til bæredygtige byer og samfund. Med omkring 1000 servicestationer, vores egen bank og et af markedets stærkeste virksomhedstilbud ønsker vi at være den foretrukne mulighed for bæredygtig forretning – både nu og i fremtiden. Læs mere på www.okq8.se
Forbind til LTI:
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200206005412/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum